Neal D. Shore, MD, FACS | Authors


Enzalutamide Use in Patients With mHSPC Who Received Prior Local Therapy

July 08, 2022

Neal Shore, MD, FACS, discusses the purpose behind investigating enzalutamide in a cohort of patients with metastatic hormone-sensitive prostate cancer who were previously treated with local therapy as a post-hoc analysis of the ARCHES study.

Darolutomide Controls Local Symptoms in nmCRPC

September 11, 2021

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.